Identification of novel therapeutic targets for diabetic neuropathy through integrated proteomics and transcriptomics approaches

Table 1 Result summary of Mendelian randomization and sensitivity analysis on the associations between plasma proteins and diabetic neuropathy

Protein	Method	nSNP	Beta	SE	P value	FDR	OR (95%CI)	MR-Egger	Q
								P value	P value IVW
MICB	Weighted median	25	-0.339	0.036	0.000	0.000	0.71 (0.66-0.76)	0.062	0.000
	MR Egger	25	-0.189	0.121	0.132	0.902	0.83 (0.65-1.05)
	Inverse variance weighted	25	-0.371	0.082	0.000	0.002	0.69 (0.59-0.81)
NOTUM	Weighted median	6	-0.526	0.198	0.008	0.473	0.59 (0.40-0.87)	0.126	0.365
	MR Egger	6	-0.067	0.321	0.845	0.993	0.94 (0.50-1.75)
	Inverse variance weighted	6	-0.611	0.161	0.000	0.024	0.54 (0.40-0.74)
WARS	Inverse variance weighted	7	0.445	0.108	0.000	0.008	1.56 (1.26-1.93)	0.781	0.512
	MR Egger	7	0.493	0.198	0.055	0.766	1.64 (1.11-2.42)
	Weighted median	7	0.457	0.123	0.000	0.031	1.58 (1.24-2.01)
HSPA1B	Wald ratio	1	-4.552	0.501	0.000	0.000	0.01 (0.00-0.03)
BTN3A1	Wald ratio	1	-2.852	0.695	0.000	0.009	0.06 (0.01-0.23)
PSMB9	Wald ratio	1	-3.272	0.854	0.000	0.022	0.04 (0.01-0.20)
SCGN	Inverse variance weighted	2	-1.415	0.375	0.000	0.026	0.24 (0.12-0.51)
CSNK2B	Wald ratio	1	1.470	0.888	0.000	0.000	4.35 (3.59-5.10)
BRD2	Wald ratio	1	0.623	0.564	0.000	0.000	1.86 (1.38-2.34)

OR: Odds ratio; CI: Confidence interval; nSNP: Number of single nucleotide polymorphisms; SNP: Single nucleotide polymorphisms; FDR: False discovery rate; MR: Mendelian randomization; IVW: Inverse variance-weighted.